Tumor progression and tumor response to anticancer therapies may be affected by activation of oncogenic pathways such as the antioxidant one induced by NRF2 (nuclear factor erythroid 2-related factor 2) transcription factor and the pathways modified by deregulation of oncosuppressor p53. Often, oncogenic pathways may crosstalk between them increasing tumor progression and resistance to anticancer therapies. Therefore, understanding that interplay is critical to improve cancer cell response to therapies. In this study we aimed at evaluating NRF2 and p53 in several cancer cell lines carrying different endogenous p53 status, using a novel curcumin compound since curcumin has been shown to target both NRF2 and p53 and have anti-tumor activity.

A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status / Garufi, Alessia; Baldari, Silvia; Pettinari, Riccardo; Gilardini Montani, Maria Saveria; D'Orazi, Valerio; Pistritto, Giuseppa; Crispini, Alessandra; Giorno, Eugenia; Toietta, Gabriele; Marchetti, Fabio; Cirone, Mara; D'Orazi, Gabriella. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 39:1(2020). [10.1186/s13046-020-01628-5]

A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status

Baldari, Silvia;Gilardini Montani, Maria Saveria;D'Orazi, Valerio;Cirone, Mara;
2020

Abstract

Tumor progression and tumor response to anticancer therapies may be affected by activation of oncogenic pathways such as the antioxidant one induced by NRF2 (nuclear factor erythroid 2-related factor 2) transcription factor and the pathways modified by deregulation of oncosuppressor p53. Often, oncogenic pathways may crosstalk between them increasing tumor progression and resistance to anticancer therapies. Therefore, understanding that interplay is critical to improve cancer cell response to therapies. In this study we aimed at evaluating NRF2 and p53 in several cancer cell lines carrying different endogenous p53 status, using a novel curcumin compound since curcumin has been shown to target both NRF2 and p53 and have anti-tumor activity.
2020
(arene)ruthenium(II) compound; autophagy; brusatol; cancer therapy; chemoresistance; curcumin; NRF2; oxidative stress; p53
01 Pubblicazione su rivista::01a Articolo in rivista
A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status / Garufi, Alessia; Baldari, Silvia; Pettinari, Riccardo; Gilardini Montani, Maria Saveria; D'Orazi, Valerio; Pistritto, Giuseppa; Crispini, Alessandra; Giorno, Eugenia; Toietta, Gabriele; Marchetti, Fabio; Cirone, Mara; D'Orazi, Gabriella. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 39:1(2020). [10.1186/s13046-020-01628-5]
File allegati a questo prodotto
File Dimensione Formato  
Garufi_Ruthenium(II)-curcumin_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.61 MB
Formato Adobe PDF
1.61 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1425013
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 24
social impact